Asahi Kasei Bioprocess (AKB), which specializes in oligosynthesis equipment, and Axolabs formed a strategic partnership in the field of oligonucleotide therapeutics. The companies will collaborate to build an oligonucleotide cGMP manufacturing facility spanning an area of 59,000 ft2 (approximately 5,481m2) in Berlin. The partners aim to accelerate the development and commercialization of oligo-based therapies.
Axolabs, a CRDMO providing drug substances for oligo-based therapeutics, is establishing a new GMP manufacturing hub in Berlin. The facility is designed to accommodate a range of production scales (small to large/commercial) and will benefit from AKB’s suite of oligo manufacturing equipment—covering all upstream and downstream manufacturing unit operations from synthesis to concentration—all of which is purpose-built to maximize productivity and provide years of reliable operation, according to Chris Rombach, SVP of sales and marketing at AKB.
“We are thrilled to join forces with Axolabs in this transformative endeavor. Our combined technical expertise and strategic alignment will bolster our commitment to meet and exceed the growing needs of the oligonucleotide therapeutics field,” said Rombach. “Moreover, our involvement from the early stages of the project allows us to support and facilitate our respective strengths.”
“We are confident that this collaboration will foster innovation and drive the production of high-quality oligonucleotide therapeutics,” added Thomas Rupp managing director of technology and production at Axolabs.
Operations at the newly built facility are planned to commence in late 2024.
